Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Unknown 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 33Neoplasms 27Colorectal Neoplasms 20Breast Neoplasms 16Ovarian Neoplasms 15Pancreatic Neoplasms 13Neoplasm Metastasis 12Lung Neoplasms 11Stomach Neoplasms 10Leukemia, Myeloid, Acute 10Melanoma 9Lymphoma, Non-Hodgkin 8Small Cell Lung Carcinoma 6Recurrence 6Liver Neoplasms 6Leukemia 6Head and Neck Neoplasms 6Fallopian Tube Neoplasms 6Prostatic Neoplasms 5Glioblastoma 5Cholangiocarcinoma 5Adenocarcinoma 5Urinary Bladder Neoplasms 4Triple Negative Breast Neoplasms 4Squamous Cell Carcinoma of Head and Neck 4Sarcoma 4Precursor Cell Lymphoblastic Leukemia-Lymphoma 4Lymphoma 4Gastrointestinal Neoplasms 4Uterine Cervical Neoplasms 3

Interventions

cemiplimab 2S 1 (combination) 2zimberelimab 1sintilimab 1quemliclustat 1pembrolizumab 1lorlatinib 1fludarabine 1WW Domain-Containing Oxidoreductase 1Pemetrexed 1Interleukin-2 1Drug Therapy 1Docetaxel 1Cyclophosphamide 1Cisplatin 1Cetuximab 1Carboplatin 1Bortezomib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Advanced Non-Small Cell Lung Cancer × Drug Therapy × Clear all
NCT05978401 2023-08-07

Safety, Tolerability, and Efficacy of GLS-012 and GLS-010 in Patients With Advanced Non-Small Cell Lung Cancer

Guangzhou Gloria Biosciences Co., Ltd.

Phase 1/2 Unknown
152 enrolled
Thoracic

Advanced Non-Small Cell Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡